Dextropropoxyphene
Severe
Database
Clinical effect not specified
Source: DDInter
Drug reference
dimenhydrinate
Ethanolamine (H1 Antagonist) · Antiemetic, Motion Sickness, Vertigo
Ethanolamine (H1 Antagonist)Antiemetic, Motion Sickness, Vertigo
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
6 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactionssee all 6 →
- DextropropoxypheneSevereDatabaseDDInter
- Potassium ChlorideSevereDatabaseDDInter
- Potassium CitrateSevereDatabaseDDInter
- Sodium OxybateSevereDatabaseDDInter
Mechanism
Not yet extracted
Indications
motion sickness (prophylactic, milder types)vertigomotion sickness
Dosing
- Adult
- 25–50 mg oral
Pharmacokinetics
Duration
12–24 hours or more
Side effects
Common
sedationdiminished alertnesslight headednessmotor incoordinationfatiguetendency to fall asleepdry mouthalteration of bowel movementurinary hesitancyblurring of visiondryness of mouth
Drug interactions
Potassium Chloride
Severe
Database
Clinical effect not specified
Source: DDInter
Potassium Citrate
Severe
Database
Clinical effect not specified
Source: DDInter
Sodium Oxybate
Severe
Database
Clinical effect not specified
Source: DDInter
Topiramate
Severe
Database
Clinical effect not specified
Source: DDInter
Zonisamide
Severe
Database
Clinical effect not specified
Source: DDInter
6 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.
Related guidelines
Other Ethanolamine (H1 Antagonist) drugs
Ask House about dimenhydrinate
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e, Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team